What is Natalizumab?

Category: Prescription Drugs

Most popular types: Tysabri Antegren

false

Natalizumab is a monoclonal antibody given by infusion and used in the treatment of MS and Crohn's disease. It has been shown to slow progression and reduce relapses in MS. 

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Multiple sclerosis 2,107 1,455
Improve mobility 49 40
General health 32 20
Fatigue 26 18
Stiffness/spasticity 20 15
Nerve pain (neuralgia) 9 12

Show all 28 reasons taken


  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 78
Moderate 132
Mild 419
None 849

Commonly reported side effects and conditions associated with Natalizumab

Side effect Patients
Headaches 94
Fatigue 67
Tiredness 66
Nausea 20
Head pain 11
Stomach pain 11

Show all 205 reported side effects

Dosages

Based on patients currently taking Natalizumab

Dosage Patients
300 mg/15 mL monthly 55
300 mg/15 mL every 4 weeks 54
300 mg/15ml every 4 weeks 39
300 mg/15ml monthly 26
300 mg monthly 4
300 mg/15 mL every 6 weeks 2
300 mg every 4 weeks 2
300 x 300 mg/15ml every 4 weeks 2
monthly 2
30 mg every 8 weeks 1

See all 16 dosages

Why patients stopped taking Natalizumab

Multiple reasons could be selected

Reason Patients
Doctor's advice 297
Other 238
Side effects too severe 194
Did not seem to work 154
Personal research 58
Course of treatment ended 30
Expense 28
Change in health plan coverage 18
See all 724 patients who've stopped taking Natalizumab

Duration

Currently taking Natalizumab

Duration Patients
Less than 1 month 1
1 - 6 months 6
6 months - 1 year 7
1 - 2 years 12
2 - 5 years 42
5 - 10 years 91
10 years or more 37

Stopped taking Natalizumab

Duration Patients
Less than 1 month 74
1 - 6 months 134
6 months - 1 year 110
1 - 2 years 170
2 - 5 years 193
5 - 10 years 43
10 years or more 6
Adherence
Adherence Evaluations
Always 1375
Usually 56
Sometimes 11
Never taken as prescribed 36
Burden
Burden Evaluations
Very hard to take 50
Somewhat hard to take 180
A little hard to take 435
Not at all hard to take 813
Cost per month
Cost per month Evaluations
$200+ 181
$100-199 50
$50-99 69
$25-49 85
< $25 541
Not specified 552

What people switch to and from

Patients started taking Natalizumab after stopping:

Treatment Patients
Glatiramer acetate (Copaxone) 81
Interferon beta-1a IM Injection (Avonex) 49
Interferon beta-1a SubQ injection (Rebif) 47
Dimethyl fumarate (Tecfidera) 35
Fingolimod (Gilenya) 26

Show all 17 treatments patients report switching from

Patients stopped taking Natalizumab and switched to:

Treatment Patients
Fingolimod (Gilenya) 42
Dimethyl fumarate (Tecfidera) 40
Ocrelizumab (Ocrevus) 25
Rituximab (Rituxan) 18
Teriflunomide (Aubagio) 14

Show all 18 treatments patients report switching to

Last updated:

112 patient evaluations for Natalizumab

Aug 16, 2018 (Started Aug 01, 2018)

  • Effectiveness
    Major (for multiple sclerosis)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 300 mg/15ml Monthly

  • 0 helpful marks

Mar 30, 2018 (Started Jul 01, 2014)

  • Effectiveness
    Major (for multiple sclerosis)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    A little hard to take
Dosage: 300 mg/15ml every 4 weeks
Cost: < $25 monthly

  • 0 helpful marks

Jul 9, 2017 (Started Jun 30, 2016)

  • Effectiveness
    Major (for multiple sclerosis)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 300 mg/15ml Monthly

  • 0 helpful marks
Last updated:
Showing 3 of 112 patient evaluations for Natalizumab